Study details
Enrolling now
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
NCT IDNCT07484022ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18+
Locations
2 sites in FL, NY
What this study is about
This Phase 1 study is testing Pembrolizumab in people with advanced urothelial cancer. The primary outcome being measured is Incidence of AEs and SAEs.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), enfortumab vedotin
Drug routes
infusion
Endpoints
Primary: Incidence of AEs and SAEs
Secondary: Pharmacokinetics of GB-4362
Body systems
Oncology